MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study Targeting Application To U.S. FDA In Second Half of 2025 PITTSBURGH , June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare... Read More

PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025 . Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A... Read More

MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating Significant Chronic Night Driving Impairment in Keratorefractive Patients With Reduced Mesopic Vision, a Condition With No Current FDA-Approved Therapies No Evidence of Tachyphylaxis Was Observed In This Study Over The 6-Week... Read More

ETOBICOKE, ON , May 27, 2025 /CNW/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in Canada of an orally disintegrating tablet of clozapine, which is the only... Read More

PITTSBURGH , May 22, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in June 2025 . The Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025 , at 8:10 a.m. ET . In addition, the Company will take part in a fireside chat at the Goldman Sachs 46 th Annual... Read More

Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH , May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed... Read More

Treatment With XULANE LO Low Estrogen Dose Achieved Primary and All Secondary Efficacy and Safety Endpoints Results Demonstrated Potential Best-In-Class Patch Performance New Drug Application Submission to U.S. FDA Anticipated in the Second Half of 2025 PITTSBURGH , May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121)... Read More

All Primary and Secondary Endpoints Were Met in Both Phase 3 Studies In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain Control Versus the Opioid Arm Targeting New Drug Application Submission to U.S. FDA by End of 2025 PITTSBURGH , May 8, 2025 /PRNewswire/ -- Viatris Inc.... Read More

PITTSBURGH , May 7, 2025 /PRNewswire/ -- Viatris Inc . (Nasdaq: VTRS) today announced that on May 5, 2025 , its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025 , to shareholders of record as of the close of business on May 23 , 2025. About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare... Read More

Directors Rajiv Malik and Harry Korman to Retire at the End of Their Current Terms PITTSBURGH , May 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Frank D'Amelio and Michael Severino , M.D. , have been appointed as the newest members of Viatris' Board of Directors. In addition, the Company announced that current... Read More

PITTSBURGH , April 25, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, will present at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV , on Tuesday, May 13, 2025 . The company's presentation will begin at 5 p.m. PT / 8 p.m. ET . A live webcast of the event at can be found at investor.viatris.com . An archived version of the presentation will be available following the live event... Read More

Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan PITTSBURGH , April 21, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has filed applications to the Ministry of Health, Labor and Welfare (MHLW) for approval of Effexor SR Capsules (venlafaxine hydrochloride), a... Read More

PITTSBURGH , April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and... Read More

PITTSBURGH , April 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. While the Company's presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters.... Read More

PITTSBURGH , March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025 . Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A... Read More

PITTSBURGH , March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025 . The company's fireside chat will begin at 2 p.m. ET . A live webcast of the event at can be found at investor.viatris.com . An archived version of the presentation will be available following the live event... Read More

Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1] Reports 2024 Total Revenues of $14.7 Billion , U.S. GAAP Net Loss of $(634) Million , Adjusted EBITDA of $4.7 Billion , U.S. GAAP Diluted EPS Loss of $(0.53) per Share, Adjusted EPS of $2.65 per Share, U.S. GAAP Net Cash Provided by Operating Activities of $2.3 Billion , and Free Cash Flow of $2.0 Billion... Read More

PITTSBURGH , Feb. 27, 2025 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ( $0.48 ) per share and declared a quarterly dividend of 12 cents ( $0.12 ) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on... Read More

PITTSBURGH , Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025 . Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for... Read More

PITTSBURGH , Jan. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 . The company's presentation and fireside chat will begin at 8:15 a.m. PT / 11:15 a.m. ET . A live webcast of the event can be found at investor.viatris.com . An archived version of... Read More

Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases PITTSBURGH , Dec. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The... Read More

Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million ; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on... Read More

PITTSBURGH , Nov. 5, 2024 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS) today announced that on November 4, 2024 , its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024 , to shareholders of record as of the close of business on November 22, 2024 . About Viatris Viatris Inc. (NASDAQ: VTRS) is a... Read More

PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List . This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people... Read More

PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Details of the presentations can be found below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m. PT / 11:45 a.m. ET Location: Terranea Resort in Rancho Palos Verdes, California Format: Fireside chat with... Read More

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH , Oct. 16, 2024 /PRNewswire/ -- Viatris Inc . (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon... Read More

Treatment with once-daily EFFEXOR ® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR ® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO , Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results... Read More

PITTSBURGH , Oct. 8, 2024 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024 . This is the fourth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider. "Our colleagues' passion for and commitment to their... Read More

After 25 years of the Viagra ® brand in Canada , Viagra ODF (orodispersible film) offers a new option for those who value convenience and discretion Erectile dysfunction (ED) affects over 50% of men aged 40 and older, resulting in pervasive impact on men's sexual health. 1 Emerging research and market trends suggest a potential role for discreet ED treatments, underscoring the importance of patients' privacy, comfort and... Read More

PITTSBURGH , Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly... Read More

PITTSBURGH , Sept. 17, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") and that UAS has increased the maximum aggregate principal amount for the Maximum Tender Offer from up to a maximum aggregate principal amount of $450,000,000... Read More

PITTSBURGH , Sept. 16 , 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024 , before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of... Read More

PITTSBURGH , Sept. 10 , 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued... Read More

PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes... Read More

PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender... Read More

Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod PITTSBURGH , Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare... Read More

Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1 Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million ; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was... Read More

PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS) today announced that on August 5, 2024 , its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 , to shareholders of record as of the close of business on August 23, 2024 . About Viatris Viatris Inc. (NASDAQ: VTRS) is a... Read More

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH , July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug... Read More

PITTSBURGH , July 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik , a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in... Read More

PITTSBURGH , June 25, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most Sustainable Companies 2024 . This recognition is presented by TIME and Statista Inc., the world-leading statistics portal and industry ranking provider. The World's Most Sustainable Companies 2024 list recognizes leading companies in... Read More

PITTSBURGH , June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024 , before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the... Read More

PITTSBURGH , June 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024 . Chief Executive Officer Scott A Smith and Company executives will represent the company in a fireside chat scheduled at 9:20 a.m. ET.... Read More

PITTSBURGH , June 3, 2024 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently... Read More

PITTSBURGH , May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024 . Chief Executive Officer Scott A. Smith and Company executives will represent the company in a fireside chat scheduled at 8 a.m. ET . Interested parties can access a... Read More

Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa : Bridging the Healthcare Divide" – a powerful new documentary short... Read More

Reports Total Revenues of $3.66 Billion ; U.S. GAAP Net Earnings of $113.9 Million ; Adjusted EBITDA of $1.19 Billion ; U.S. GAAP EPS of $0.09 ; Adjusted EPS of $0.67 ; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million ; and Free Cash Flow of $565 Million for the First Quarter Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] Reaffirms 2024 New Product... Read More

PITTSBURGH , May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024 . Chief Financial Officer Doretta Mistras and Chief R&D Officer Philippe Martin will represent the company in a fireside chat scheduled at 10 a.m. PT / 1 p.m. ET.... Read More

PITTSBURGH and LONDON , May 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently launched Unmind as part of its global wellbeing program, Elevate. Unmind is a leading provider of workplace mental health solutions designed by psychologists to help individuals understand and be proactive with their mental health and lead healthier, happier lives. "The mental wellbeing of our colleagues is... Read More

PITTSBURGH , April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024 , before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call... Read More

PITTSBURGH , April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and... Read More

New generic Multiple Sclerosis treatment option, Pr Glatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world ETOBICOKE, ON , April 15, 2024 /CNW/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the launch in Canada of Pr Glatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of... Read More

PITTSBURGH , April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI ™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States. RYZUMVI is now the only U.S. commercially... Read More

PITTSBURGH , March 27, 2024 /PRNewswire/ -- At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its R&D strategy to deliver on its goal of building a more durable, higher-margin portfolio of patented innovation on the foundation of its strong base business. The focus of the event will be a discussion of its collaboration with... Read More

Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] Reports 2023 Total Revenues of $15.4 Billion , U.S. GAAP Net Earnings of $54.7 Million , Adjusted EBITDA of $5.1 Billion , U.S. GAAP Net Cash Provided by Operating Activities of $2.8 Billion and Free Cash Flow of $2.4 Billion Reports Third Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis in 2023 and Expects to see... Read More

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand Collaboration With Additional Innovative Assets Combines Viatris' Financial Strength and Worldwide Operational Infrastructure With Idorsia's Proven, Highly Productive Drug Development Team and Innovation Engine Deal Structure... Read More

PITTSBURGH , Feb. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024 , before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of... Read More

PITTSBURGH , Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 . Chief Executive Officer Scott A. Smith , President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a presentation followed by a fireside chat... Read More

Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial... Read More

Board of Directors Elects Melina Higgins New Chair PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced that at its 2023 Annual Meeting of Shareholders held today, shareholders voted to re-elect all nominated Directors and approved/ratified all voting matters. The official voting results for each item voted on by shareholders will be disclosed in a current report on... Read More

PITTSBURGH , Nov. 14, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023 . Chief Executive Officer Scott A. Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula will represent the Company in a fireside chat scheduled at 4:30 a.m. ET / 9:30... Read More

Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the... Read More

Reports Total Revenues of $3.94 Billion ; U.S. GAAP Net Earnings of $332 Million ; Adjusted EBITDA of $1.36 Billion ; U.S. GAAP Net Cash Provided by Operating Activities of $834 Million ; and Free Cash Flow of $738 Million for the Quarter Strong Results Signal Continuation of Growth Journey with Second Consecutive Quarter of... Read More

PITTSBURGH , Oct. 30, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today it is hosting The Power of Partnership to Address Antimicrobial Resistance (AMR) , a Nasdaq webinar that will air on Tuesday, November 14, 2023 at 9 a.m. ET . AMR is a significant threat to global health and economic development. As the progression of AMR renders antibiotics less effective, common infections,... Read More

PITTSBURGH , Oct. 23, 2023 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2023 . Viatris has received this recognition in each of its first three years since forming in 2020. This recognition is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider. "Being recognized again... Read More

PITTSBURGH , Oct. 20 , 2023 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company effective April 1, 2024 . Malik is a nearly 40-year pharmaceutical industry veteran who has been responsible for the day-to-day operations of Viatris since its inception, overseeing the Company's commercial business units, the... Read More

PITTSBURGH , Oct. 18, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it has been named to 3BL's annual 100 Best Corporate Citizens ranking, recognizing outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies. 3BL is a news distribution platform that promotes ESG initiatives of leading companies and... Read More

PITTSBURGH , Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets. Chief Executive Officer Scott A. Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 5:00 p.m. ET on November 7 to discuss the results. Investors and the general public are... Read More

Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously Communicated Range Strategic Decision Made to Retain Rights and Opportunities for Viagra®, Dymista® and Select Over-the-Counter (OTC)... Read More

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 PITTSBURGH , and FARMINGTON HILLS, Mich. , Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye... Read More

PITTSBURGH , Sept. 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list . This recognition of companies changing the world is presented by TIME, the 99-year-old global media brand and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the... Read More

Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries PITTSBURGH and BANGALORE, India , Sept. 5, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60... Read More

Reports Total Revenues of $3.92 Billion ; U.S. GAAP Net Earnings of $264 Million ; Adjusted EBITDA of $1.31 Billion ; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million ; and Free Cash Flow of $447 Million for the Quarter Strong Results Signal Expected Beginning of Growth Journey Reaffirms that Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow Expected to be at Midpoint of 2023 Guidance Ranges[1]... Read More

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and continued commitment toward addressing the unmet needs of the MS community PITTSBURGH and NESS ZIONA, Israel , Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully... Read More

Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access PITTSBURGH and WOODBURY, Minn. , July 31, 2023 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide... Read More

PITTSBURGH , June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on August 7 to discuss the results. Investors and the general public are invited to... Read More

PITTSBURGH , May 30, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to USA Today's inaugural list of America's Climate Leaders 2023 for companies that have demonstrated the greatest reduction in emissions intensity. The list was compiled by USA Today and market research company Statista, the world-leading statistics portal and industry ranking provider.... Read More

Coury will serve in this new role until the end of 2025 PITTSBURGH , May 22, 2023 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, announced today that as a result of the strength and stability that Viatris has achieved since its formation in 2020, including its ninth consecutive quarter of solid execution and performance, as well as the successful completion of the integration of its two legacy... Read More

PITTSBURGH , May 22, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris' newest member of its board of directors. Groothuis fills the vacancy created by the previous departure of Michael Goettler in April of this year. Groothuis has significant international experience and serves as... Read More

PITTSBURGH , May 17, 2023 /PRNewswire/ -- Viatris Inc. ( NASDAQ : VTRS ), a global healthcare company, today announced the company will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA on Tuesday, June 13, 2023 . Chief Executive Officer Scott A. Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula will represent the Company in a fireside chat scheduled at 1:20... Read More

Supplied medicines to approximately 1 billion patients globally PITTSBURGH , May 16, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2022 Sustainability Report showcasing its commitment, impact and progress on building sustainable access to medicine as it continues to make a positive difference across key areas including Access and Global Health, Our People, the Environment... Read More

Reports Total Revenues of $3.73 billion ; U.S. GAAP Net Earnings of $225 million ; Adjusted EBITDA of $1.34 billion ; U.S. GAAP Net Cash Provided by Operating Activities of $971 million ; and Free Cash Flow of $923 million for the Quarter Expects Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow to be at Midpoint of 2023 Guidance Ranges[1] Reaffirms 2024 Phase 2 Outlook from November 7 Strategic Update Returns... Read More

Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) PITTSBURGH , April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in... Read More

PITTSBURGH , April 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets. Chief Executive Officer Scott Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on May 8 to discuss the results. Investors and the general public are invited to listen... Read More

Innovative online education platform helping global healthcare professionals address non-communicable diseases PITTSBURGH and WASHINGTON , April 6, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and the American College of Cardiology (ACC) today released the latest NCD Academy course, Health Equity and Social Determinants of Health in NCDs, coinciding with World Health Day and the theme... Read More

All Pending Claims Have Been Dismissed PITTSBURGH , March 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) announced that the U.S. District Court for the Southern District of New York has dismissed all claims against the Company in their entirety and granted its motion for summary judgment in the securities class action related to the Company's marketing, pricing, and classification of EpiPen, as well as alleged conduct... Read More

Smith, a seasoned senior healthcare executive, will lead the company's previously announced Phase 2 strategy and execution Board of Directors thanks Michael Goettler , who will support a smooth transition prior to his departure PITTSBURGH , Feb. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as it prepares to enter Phase 2 of its previously announced strategic plan in... Read More

Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quarter Impact of the Biosimilars Transaction and Acquired IPR&D 2023 Guidance Midpoint Reflects Revenue Growth Over 2022, Excluding Full-Year Impact of Biosimilars Reaffirms 2024 Phase 2 Outlook from November 7 Strategic Update Company Increases Return of Capital to Shareholders by Completing $250 Million in Share Repurchases Board of Directors Approves... Read More

PITTSBURGH , Feb. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its fourth quarter and full year 2022 financial results on Monday, February 27 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on February 27 to discuss the results. Investors and the general... Read More

Division Combines Oyster Point Pharma's Eye Care Expertise with Famy Life Science's Phase III-ready Pipeline and Lays Foundation for Viatris to Become a Global Eye Care Leader Acquisitions Have the Potential to Add at Least $1 Billion in Sales by 2028 Transactions Showcase the Power of Viatris' Global Healthcare Gateway® PITTSBURGH , Jan. 3, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today... Read More

Directors Neil Dimick and Ian Read Retire PITTSBURGH , Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors. Smith and Finney fill the vacancies created by the retirement of Neil Dimick and Ian Reid . Scott Smith is a deeply experienced global biotechnology and... Read More

PITTSBURGH , Dec. 23, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11 , 2023. Representing Viatris will be Chief Executive Officer Michael Goettler , President Rajiv Malik , Chief Financial Officer Sanjeev Narula and joined by Jeff Nau , CEO of Oyster... Read More

The contribution includes donations to four organizations: Direct Relief, World Central Kitchen, WaterAid and World Food Program USA PITTSBURGH , Dec. 14, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it is donating a total of $1 million to aid in supporting access to healthcare, food security and water stewardship in communities around the world, through four organizations:... Read More

PITTSBURGH , Dec. 14, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that its near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). SBTi is a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science. Viatris President Rajiv Malik said, "This approval from... Read More